What Is Interferon Beta-1a?

Recombinant human interferon 1a injection with indication for relapsing multiple sclerosis

Drug type: Blood bioproducts
Drug Name: Recombinant human interferon 1a injection

Drug type: Prescription drugs, medicines for medical workers' injuries
Use classification: Immune enhancer

Recombinant human interferon 1a injection components

Recombinant human interferon 1

Characteristics of recombinant human interferon 1a injection

Lyophilized white sterile powder in ampoules

Indications of recombinant human interferon 1a injection

This product is suitable for patients with multiple sclerosis (MS) who have had at least 2 relapses in the past two years

Usage and dosage of recombinant human interferon 1a injection

The lyophilized powder should not be used until completely dissolved. Labial herpes, genital herpes, and shingles: Extensive or only slow-responding herpetic lesions, systemic administration, intramuscular injection, at a dose of 2 million IU / day for 10 consecutive days. Flat and condyloma acuminata: 1 to 3 million IU / day for 5 days in a row, 1 week as a cycle, 1-3 cycles each time, intra- or intra-lesion injection; or intramuscular injection of 2 million IU / day, continuous 10 days. It is best to use intramuscular injection for multiple lesions, or when drugs injected into and around the lesion have difficulty entering the lesion. Chronic viral hepatitis:-Hepatitis B: The best drug regimen has not yet been found. The recommended dose is: 5 million IU / m 2 of body surface area, intramuscular injection, 3 times a week for 6 months. If the HBeAg level, a hallmark of viral replication, does not decrease after 1 month of administration, increase the dose. The dosage can be adjusted according to the patient's tolerance to the drug. If the condition does not improve after 3-4 months of treatment, drug withdrawal should be considered. Hepatitis C and E: No optimal drug regimen has been found. The recommended dose is: 6 million IU / body surface area, intramuscular injection, 3 times a week for the first 2 months, and then changed to 3 million IU intramuscular injection, 3 times a week, for 3-6 months. The therapeutic effect was judged based on the level of transaminase within 16 weeks. If the condition does not improve after 16 weeks of treatment, drug withdrawal should be considered. There is not much experience in the effect of repeated treatment. Cervical intraepithelial tumor: 3 million IU / day, injected intralesionally for 5 days, and then injected 3 million IU every other day for 2 weeks. Tumorous pleural effusion: After thoracentesis, 5 million IU of this product (diluted with 50 ml of normal saline) is injected into the pleural cavity. If pleural effusions appear again after 7-15 days, perform chest puncture and inject 10 million IU (diluted with 50 ml of normal saline) into the pleural cavity. If it recurs after 15 days, 20 million IU of the drug is injected into the pleural cavity with 50 ml of normal saline. Hair cell leukemia induction dose: 6 million IU / body surface area / day, intravenous infusion slowly, for 7 days in a row, sharing 3 cycles, with an interval of 1 week between each cycle. Maintenance dose: 6 million IU / body surface area, slow intravenous infusion, twice a week for 24 weeks. Induction of steroid hormone receptors in breast tumors and endometrial tumors: intramuscular injection of 2-6 million IU / time, once every other day for a total of 2 weeks. This treatment can be repeated every 4 weeks during hormone therapy

Adverse reactions of recombinant human interferon 1a injection

The patient's electrolyte balance and blood image should be closely monitored during the use of this product. If the white blood cell, platelet, and hemoglobin counts reach critical values, the blood count should be checked 1-2 times a week. If prolonged prothrombin occurs, this parameter should be monitored daily. Cardiovascular and central nervous system side effects may occur when used parenterally. Parenteral use of human interferon beta, especially at high daily doses, may cause increased body temperature, weakness, muscle pain, and occasional headaches, nausea, and vomiting. According to reports, the following symptoms may occur during prolonged treatment: leukopenia, decreased platelet count, anemia, prolonged prothrombin time, transient increase in transaminase, tachycardia, loss of appetite, bone and joint pain, lethargy, insomnia, diarrhea , Hypotension, dyspnea and hair loss. However, these side effects are reversible even with continued long-term treatment. If high fever (above 40 ° C) with prolonged chills, vomiting, and unstable blood pressure, medication should be suspended or appropriately reduced.

Restriction of recombinant human interferon 1a injection

People who are allergic to natural or recombinant interferon beta, albumin human or other ingredients.

Precautions for recombinant human interferon 1a injection

1. For patients who are depressed or suicidal, monitor carefully.
2. For authors who have a history of epilepsy, or no history of epilepsy during treatment, should be carefully monitored.
3. When used in patients with a history of angina pectoris, heart failure, arrhythmia, etc., it should be carefully monitored.
4. Pregnancy classification: C
5. The safety and benefits of children under the age of 18 have not yet been established.
6. During the treatment, whole blood cells, the number of differentiated white blood cells, platelets and liver function (at least every six months) should be monitored. For patients with suppressed bone marrow function, more complete monitoring of whole blood cells, differentiated white blood cells and Platelets.

Drug Interactions of Recombinant Human Interferon 1a Injection

No studies have been conducted on the interaction of this product with other drugs in the human body. Interferon has been reported to reduce liver cytochrome P-450 dependent enzyme activity in humans and animals. Caution should be used when combining this product with drugs with narrow therapeutic indices (such as antiepileptics or certain types of antidepressants) that rely heavily on the clearance of the liver's cytochrome P-450 system. No systematic studies have been conducted on the interaction of this product with corticosteroids or adrenocorticotropic hormones. Clinical studies have shown that patients with multiple sclerosis can be treated with this product and corticosteroids or corticosteroids during the relapse period.

Recombinant human interferon beta 1a injection for pregnancy and lactation

This product has not been studied in pregnant women. In monkeys, the use of other large doses of interferon can cause miscarriage (see section "Pharmacology and Toxicology"). This effect cannot be ruled out in humans. Women of childbearing age receiving this product must take appropriate contraception. Patients who are planning to conceive or are pregnant should tell her about the harm the product may cause to the fetus and discontinue treatment with this product. It is unclear whether this product can enter breast milk. Because breastfeeding may cause serious adverse reactions, you must stop breastfeeding or discontinue treatment with this product.

Pharmacology and toxicology of recombinant human interferon 1a injection

Interferon -1a is a 166 amino acid-containing glycoprotein produced by mammalian cells (Chinese hamster ovary cells). The amino acid sequence is the same as that of human interferon. Interferon has antiviral, antiproliferative, and immunomodulatory effects, but its mechanism of action in relapsing multiple sclerosis has not been fully understood.

Pharmacokinetics of recombinant human interferon 1a injection

Within 12 hours after administration, the concentration of blood reactants (such as neopterin, 2microglobulin) increased and maintained for at least 4 days, usually reaching the highest value 48 hours after administration.